OS Therapies (NYSE:OSTX) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of OS Therapies (NYSE:OSTX) in a research report released on Wednesday,Benzinga reports. D. Boral Capital currently has a $20.00 price target on the stock.

Separately, Maxim Group started coverage on shares of OS Therapies in a report on Tuesday, November 26th. They set a “buy” rating and a $8.00 target price on the stock.

OS Therapies Trading Down 9.6 %

Shares of OSTX opened at $3.94 on Wednesday. OS Therapies has a 1-year low of $1.58 and a 1-year high of $7.00. The company has a 50 day moving average of $3.29.

Institutional Investors Weigh In On OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC acquired a new position in shares of OS Therapies Inc (NYSE:OSTX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.